Crossmark

Chimeric Antigen Receptor (CAR)-NK92 cells effective against glioblastoma, breast- and pancreatic cancer in vitro and in a murine xenograft model of ovarian cancer

Crossref DOI link: https://doi.org/10.1186/s12935-025-03865-0

Published Online: 2025-07-11

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Boulifa, Abdelhadi

Franzén, Alexander Sebastian

Raftery, Martin J.

Radecke, Clarissa

Pecher, Gabriele
Funding

Funding for this research was provided by:

Charité - Universitätsmedizin Berlin
License Information

Text and Data Mining valid from 2025-07-11

Version of Record valid from 2025-07-11
More Information

Article History

Received: 10 December 2024

Accepted: 13 June 2025

First Online: 11 July 2025

Declarations

:

: Not applicable.

: All authors have agreed to the publication.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below